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ABSTRACT 
Alzheimer’s disease (AD), identified over 100 years ago and intensively 
studied since the 1970s, has no effective treatments or mechanistic 
understanding of the underlying neurodegenerative process. Most investigators 
believe accumulation or aggregation of amyloid beta (A) proteins plays a 
causative role. Aβ peptides (~39-43 residues) are generated by proteolysis of the 
transmembrane protein APP. One reason we know so little about AD is an 
incomplete understanding of the cellular mechanisms responsible for A 
proteotoxicity. Human ES and iPSC models of AD are recent additions to many 
other models used to investigate these mechanisms. AD, however is a chronic 
progressive condition of old age and cultured neurons may not live long enough 
to model what goes wrong in neurons from AD patients. In my research, I used 
hESCs which directly express A peptides thus avoiding the time it takes to 
process APP. One App allele in H9 hESCs was previously edited using TALEN. 
A homologous recombination cassette coding directly for a secretory form of 
either A1-42 or A1-40 and containing a stop codon, was inserted into the first 
exon of App upstream of the normal translational start site. I used multiple 
independently isolated clones of edited cells with 3 genotypes: App/App 
(unedited), App/Aβ1-40 and App/Aβ1-42. Expression of A from edited alleles was 
confirmed by qRT-PCR using primers specific for the edit. I first sought to 
establish if editing changed any aspects of neuronal differentiation in culture. All 
3 genotypes have similar embryoid body (EB) development, and similar numbers 
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and sizes of neuronal clusters (NC) up to 34 days after EB dissociation and 
neural differentiation. Immunostaining of neuronal markers, NeuN and DCX 
(doublecortin), likewise revealed no difference among edited and unedited cells, 
suggesting that the edits do not affect the ability of my stem cells to differentiate 
into neurons. I next measured accumulation of aggregated A using an 
aggregate specific antibody, 7A1a. Data at 34-days post EB dissociation 
indicates NCs in the Aβ1-42 edited cells accumulate significantly more aggregates 
relative to either unedited or A-40 edited lines, a result consistent with the 
increased ability for A1-42 to form aggregates. Aβ aggregates also appear to be 
concentrated around fragmented nuclei within neuronal clusters suggesting that 
intracellular accumulation may play a key role in proteotoxicity. Additionally, I 
observed a significant decrease in the number of synapsin1 puncta, a marker of 
synapses, another feature of AD. I documented a nearly 3-fold greater neuronal 
cell death in both the Aβ1-40 and Aβ1-42 neurons at 70 days after differentiation. 
RNA sequencing data also shows independently isolated clones group together 
and show differential expression of genes related to memory and neuronal cell 
death. The early presence of Aβ aggregation and subsequent cell death is in line 
with the chronic and progressive nature of AD and this is the first known model to 
exhibit a neurodegenerative phenotype. These isogenic cell lines thus appear to 
be useful to screen for therapeutics that may prevent or slow A1-42 dependent 
neurodegeneration and a tool to investigate A-dependent mechanisms with 
relevance to AD. 
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CHAPTER ONE 
ALZHEIMER’S IS A CHRONIC, PROGRESSIVE, 
AND COMPLEX DISEASE 
Background 
Alzheimer’s Disease (AD) is the most common form of dementia and the 
6th leading cause of death in the United States (“FastStats - Leading Causes of 
Death,” 2016). Symptoms include memory loss, cognitive impairment, behavioral 
changes, depression, and progressive neurodegeneration. The number of 
affected individuals is expected to increase almost four-fold by 2050 (Hebert, 
Weuve, Scherr, & Evans, 2013). While AD is devastating for patients, it also 
places burdens on their families, caregivers, and society. The average time from 
diagnosis to death is eight years and not every family has the insurance or 
financial resources to support the costs of long-term care often required for AD 
patients. While a patient’s family can usually act as caregivers in the early stages 
of the disease, professional care or hospitalization is required as the disease 
progresses. The cost of long term care for patients is expensive and families 
frequently rely on inadequately funded public support programs. The emotional 
burdens belong only to the patient and their family but the financial burden is 
often shared by both the family and society. 
Despite intensive research since the 1970s no cure or effective treatment 
has been found for AD. Part of the difficulty in finding an effective treatment lies 
with how little we understand about the mechanism of amyloid beta (Aβ) toxicity 
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in AD. This mechanism has been difficult to establish in part because 
accumulation of Aβ precedes its downstream pathological effects in the brain 
which may take decades to develop. An additional problem is that most 
laboratory AD models do not show significant neurodegeneration as part of their 
phenotype even though this is the major cellular aspect of the disease (Bales, 
2012). 
Neuropathology 
Alois Alzheimer, in his discussion of his patient Auguste D., recognized 
two hallmark neuropathological lesions: senile plaques and neurofibrillary tangles 
(NFTs). These remain the best established post-mortem diagnostic criteria for 
AD. Plaques are primarily extracellular aggregates composed of several protein 
and non-protein components, but their major constituent is a small neurotoxic 
peptide called Aβ1-42. NFTs are intracellular aggregates of a hyperphosphorylated 
form of microtubule associated protein tau. 
Plaque numbers, despite being a hallmark lesion of AD, don’t correlate 
strongly with AD symptoms such as memory loss or early stages of dementia. 
They accumulate in the brain of AD patients before tangles in both AD and AD 
models and are often a feature of non-affected brains in older individuals. 
Tangles, while correlating better with symptoms, are not unique to AD but are a 
characteristic lesion of many other neurodegenerative (ND) diseases referred to 
as tauopathies (Serrano-Pozo, Frosch, Masliah, & Hyman, 2011). 
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Proteolytic Production of Aβ 
The A1-42 peptide found in plaques is generated by proteolysis of a large 
transmembrane protein, amyloid precursor protein (APP) along with several other 
A peptides of differing length (39-43 amino acids) as well as other APP 
fragments (Haass, Kaether, Thinakaran, & Sisodia, 2012). The first step in the 
amyloidogenic pathway is cleavage of the extracellular domain by an enzyme 
called β-secretase. In the second step, a large 4 component protease, -
secretase, cleaves the APP in the intramembranous region (Figure 1). The most 
common peptide is A1-40 along with A1-42. Significantly, rare autosomal 
dominant genetic forms of AD contain mutations in either the App gene itself or in 
two other genes (Psen1 or Psen2) which form the active proteolytic site of -
secretase. In addition to this pathogenic amyloid processing pathway there is an 
additional proteolytic pathway (non-amyloidogenic) which does not appear to be 
involved in AD. This non-amyloidogenic pathway starts with an initial cleavage of 
APP at a site within the N-terminus of A1-42 thus preventing Aβ formation via -
secretase. 
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Figure 1. Aβ Formation via the Amyloidogenic Pathway.  
In the amyloidogenic pathway β-secretase first cleaves APP and 
subsequently γ-secretase, resulting in 39-43 amino acid-long Aβ 
formation. The reason for the range in the length of Aβ peptides 
produced is that the active site in -secretase (PSEN1 or PSEN2) is 
not precise in its cleavage of APP, but the most common Aβ 
peptides formed are Aβ1-40 and Aβ1-42. In the non-amyloidogenic 
pathway (bottom), α-secretase first cleaves APP within the Aβ 
sequence which prevents subsequent cleavage by-secretase and 
Aβ formation. 
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Where is Aβ Produced? 
Aβ is generated both extracellularly at the plasma membrane as well as 
intracellularly in the endoplasmic reticulum (ER), Golgi, lysosomes, and 
endosomes although the quantitative importance of production at these different 
sites is not known (Choy, Cheng, & Schekman, 2012; Hartmann et al., 1997; 
Sisodia, 1992).  
Both A1-42 and A1-40 are known to form a variety of oligomeric and higher 
ordered aggregated structures. Many investigators believe that oligomeric A1-42 
is the primary toxic form, consistent with its increased tendency to form 
aggregates relative to A1-40. This may be a result of A1-42 being more 
hydrophobic by having an additional C-terminal Leucine and Alanine residues 
(Kang et al., 1987; Soto, Brahes, Alvarez, & Inestrosa, 1994). The mechanism of 
toxicity however is still not understood. Data is available for altered mitochondrial 
function, microtubule structure, ion channels, and various components of the 
intracellular membrane trafficking pathways such as autophagy, endosomal and 
lysosomal vesicles (C Ballatore, Lee, & J, 2007; Kanae Iijima-Ando et al., 2009; 
Lin, Bhatia, & Lal, 2001; Martinez-Vicente, 2015). Aβ production as well as 
aggregation is consistently observed in intracellular vesicles but it is still debated 
if this compartment plays a primary role in toxicity or if the extracellular Aβ 
plaques are more important. Notably, conditions favorable for in vitro Aβ 
oligomerization include a high concentration of Aβ peptide and an acidic 
environment, both of which are not likely present in extracellular compartments 
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but common in intracellular organelles such as lysosomes and late endosomes 
(Hu et al., 2009). Additionally, intracellular Aβ accumulation appears before 
extracellular accumulation and the ER is the main site of intracellular Aβ 
oligomerization (Meli et al., 2014; Oddo, Caccamo, Smith, Green, & LaFerla, 
2006). 
Tau Tangle Formation and Its Pathological Appearance in AD 
Tau, also known as neuronal microtubule associated protein tau, normally 
plays a role in the outgrowth of neuronal processes by promoting microtubule 
stability and assembly (Z. Liu et al., 2015). Association of tau with microtubules is 
mostly dependent on its phosphorylation status. Unphosphorylated tau attaches 
readily to microtubules and promotes their stability. Phosphorylation of Tau 
causes separation from microtubules which allows cellular cargo to pass (Carlo 
Ballatore, Lee, & Trojanowski, 2007). Hyper-phosphorylation of tau at specific 
sites creates unstable microtubules and cytoplasmic tau begins to form paired 
helical filaments that aggregate into NFTs within the cell (Z. Liu et al., 2015; 
Virginia M.-Y. Lee, Brian J. Balin, Laszlo Otvos, 1991).  
While both Aβ plaques and NFTs likely contribute to neuronal death, Aβ 
accumulation as well as plaque formation precedes and may even induce NFT 
formation (Götz, Schild, Hoerndli, & Pennanen, 2004). Immunotherapy studies in 
mice targeting A and reducing its accumulation also result in a reduction in the 
levels of intracellular phosphorylated tau (Frank M LaFerla, 2010). Following 
cessation of immunotherapy Aβ pathology reappears before NFTs.  
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Vesicular Accumulation in AD 
Abnormal accumulation of vesicles is another well documented 
pathological hallmark of AD, as well as many AD models (Nixon, 2006). These 
vesicles often express markers of autophagy, endosomal and lysosomal (AEL) 
subcellular compartments and may thus be fusions of these ordinary types of 
vesicles. Aggregated Aβ is present within AEL vesicles both intracellularly as well 
as in extracellular space (Ihara, Morishima-Kawashima, & Nixon, 2012). Neurons 
normally experience a high rate of vesicular turnover and the increase in number 
as well as size of AEL vesicles in AD or models suggests that their turnover 
efficiency is diminished and they are thus dysfunctional (Ling, Magallanes, & 
Salvaterra, 2014). Fusion of endosomes or autophagosomes with lysosomes is 
considered the end stage leading to vesicular cargo digestion allowing the 
digested components to be reused for cellular biosynthetic functions. In AD and 
AD models the vesicular fusion pathways apparently still operate normally but the 
cargo is no longer being digested thus preventing vesicular turnover. 
The Genetics of AD 
AD can be divided into two general forms: sporadic (SAD) and familial 
(FAD). Like its name suggests, FAD exhibits an autosomal dominant inheritance 
pattern as a result of causative mutations in one of three genes present in two or 
more generations of relatives (Kovacs & Tanzi, 1998). There are no 
distinguishing characteristics of FAD and SAD other than the observation that 
FAD patients develop symptoms at a relatively younger age (also known as early 
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onset AD, EOAD). The three genes mutated in FAD are APP, Presenilin 1 
(PSEN1), and Presenilin 2 (PSEN2) (Bertram, Lill, & Tanzi, 2010). FAD 
mutations in APP can be located within the Aβ1-42 sequence but are usually 
located at or very near the cleavage sites of α-secretase or β-secretase (Weggen 
& Beher, 2012). Either PSEN1 or PSEN2 forms the active site of a four subunit 
protease complex, γ-secretase, necessary for amyloidogenic processing of APP 
into Aβ (Zheng & Koo, 2011). All known forms of FAD result in more efficient 
production of A1-42 over A1-40 providing the strongest evidence in favor for the 
amyloid hypothesis of AD: A1-42 is causative (Selkoe & Hardy, 2016). Additional 
evidence comes primarily from transgenic mouse models of AD where agents 
known to slow or prevent APP proteolysis into A1-42 (or even remove A1-42 
aggregates) generally decrease the severity of AD-like phenotypes in these 
models (Vardy, Catto, & Hooper, 2005). Unfortunately, it has not yet been 
possible to translate these findings into patient treatments as all clinical trials 
based on these mouse models have failed. Recent versions of the amyloid 
hypothesis postulate that the production and aggregation of Aβ1-42 may cause 
subsequent plaque formation, tau tangle formation, and subsequently 
neurodegeneration but the mechanistic details involved are still poorly 
understood. 
In addition to APP, PSEN1, and PSEN2, genome wide associated studies 
in individuals diagnosed with AD have identified several genes associated with a 
higher incidence of AD risk (Lambert et al., 2013). The earliest identified and 
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quantitatively most important among these is the presence of a risk allele of 
apolipoprotein E (APOE) (Kanekiyo, Xu, & Bu, 2014). APOE has three alleles 
(ε2, ε3, and ε4). Individuals carrying just one copy of ε4 have up to a four-fold 
increase in the likelihood of developing AD and copies correlates with an 
increased risk by almost fifteen-fold (Farrer et al., 1997). Interestingly, APOE ε4 
carries an increased risk in both FAD and SAD (Liu, Kanekiyo, Xu, & Bu, 
2013)(C.-C. Liu et al., 2013). APOE normally functions in cholesterol metabolism. 
APOE4 promotes oligomerization of Aβ peptides and is also found in tangles 
(Castano et al., 1995). Other studies as well as our own genomic sequencing 
data shows the H9 cell line used in our model is heterozygous ε3/ ε4 (Funk et al., 
2012). 
Current Models 
The most common models of AD are constructed in mice, invertebrates, or 
cell lines. The predominant models used for preclinical development of AD 
treatments are transgenic mice (Frank M. LaFerla & Green, 2012). Mouse 
models have been extremely successful in identifying the proteolytic processing 
mechanisms for production of Aβ as well as accumulation of plaques, but they 
have been less successful in modeling other types of AD pathology. Most 
extensively studied mouse models rely on overexpression of one or more mutant 
forms of a human AD causative transgene. Some models even use additional 
mutations in other genes not known to be affected in AD to achieve AD-related 
phenotypes. Notably, FAD patients have only a single mutation in one of the 
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three causative genes (APP, PSEN1, PSEN1) while SAD cases have no known 
cause. It is thus hard to interpret transgenic mouse results with respect to AD.  
Perhaps the two biggest phenotypic deficiencies in nearly all mouse 
models is the absence of significant neurodegeneration and the lack of tangles 
(Alzforum, 2016). More recent mouse models were designed to replace the 
endogenous mouse App gene with a copy of a mutant human gene. This 
strategy has eliminated potential problems caused by overexpression, but these 
animals still require human APP processing using mouse proteins and 
neurodegeneration has not been reported (Saito et al., 2014). 
Invertebrate models of AD often rely on direct expression of Aβ1-42 
transgenes (Gutierrez-Zepeda & Luo, 2004; K Iijima-Ando & Iijima, 2009). This 
strategy results in models exhibiting an impressive array of AD-like phenotypes 
including selective accumulation of A1-42, chronic age-dependent neurological 
deficiencies, and significant neurodegeneration (Cowan, Shepherd, & Mudher, 
2010; Kanae Iijima-Ando & Iijima, 2010).  
One drawback is that they share an absence of tangle formation just as in 
mouse models. Remarkably, a few mouse models have also been examined 
using direct expression of A and they share the robust neurodegeneration 
phenotypes with invertebrates but are not widely used or no longer available 
(Abramowski et al., 2012; LaFerla, Tinkle, Bieberich, Haudenschild, & Jay, 1995; 
Lewis et al., 2001). Though animal models have given us a great deal of 
knowledge about AD, the species differences between humans and animals are 
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increasingly being appreciated and could play a significant role in the limitations 
of current AD models. 
An obvious way to overcome species differences is to create human 
embryonic stem (hES) or induced pluripotent stem (iPS) cell models of AD. Two 
general approaches have been used: converting iPSCs from AD patient derived 
cells into neurons or genomic editing to introduce AD mutations into hES or iPS 
cells. The first strategy has been used by several groups with promising results 
(Kondo et al., 2013; Yagi et al., 2011; Yang, Li, He, Cheng, & Le, 2016).  
One drawback of iPSC studies is the absence of a proper control cell line. 
Age matched non-AD cells have been used but these are likely to have a host of 
genetic variants that may complicate simple direct interpretations of AD-like 
phenotypes. This can be avoided by using genetic editing technologies. 
However, it is still difficult to imagine how cell models can be experimentally 
analyzed long enough to view age-dependent changes. Most stem cell culture 
experiments last for a few months at the most and AD takes decades to develop 
in humans (McGowan, Eriksen, & Hutton, 2006). Some progress has be made in 
solving these aging problems, primarily by stressing the cells or incorporating 
expression of genes with accelerated aging phenotype (Studer, Vera, & 
Cornacchia, 2015). My model has taken a different approach. First, genetic 
variance is limited by using a standard well characterized human embryonic stem 
cell as a starting point. Second, my cells have been genomically edited to directly 
express a secretory form of A thus avoiding the time it would take to 
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proteolytically process APP peptide. This strategy also allows phenotypic 
characterization of A1-42 and A1-40 separately, something impossible to do in 
APP models. A1-40 which is largely non-toxic in invertebrate direct expression 
models and less toxic in mouse direct expression models. The A1-42 edited cell 
lines I observed thus have the potential to serve as an editing control. While not 
specifically a model of AD per se, we hypothesize that this system of isogenic 
lines will represent a new tool that can be used to understand the consequences 
of A1-42 accumulation that result in AD-like neurodegeneration. The final feature 
of these cells is that the edits are incorporated into the App gene itself and is thus 
not an overexpression model but rather relies on expression control from the 
normal App regulatory elements. 
Constructing a New Human ES Cell Based Model 
All cell lines used in this study were derived from the well-defined and 
established WA09 hESC line (referred to herein as H9). Multiple independently 
isolated clones were established following transcription activator-like effector 
nuclease (TALEN) genomic editing. We targeted a sequence in the first exon 
upstream of the translation initiation site in App by designing TALEN pairs that 
introduce a double strand break (DSB). The DSB was repaired in the presence of 
a plasmid containing a cassette constructed of a left and right homology arm 
(flanking the targeted cutting site), a secretory signal sequence (from the R.rattus 
preproenkephin gene), either an Aβ1-40 or A1-42 coding sequence followed by a 
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drug selection gene and a polyA tail using normal homology directed repair. This 
resulted in a secretory form of either A1-42 or A1-40 peptide under the control of 
the normal App promoter. The secretory signal directs expression routing through 
the normal secretory pathway as known for APP and the secretory signal is 
completely removed during normal secretory processing. Multiple independently 
isolated clones were obtained and examined for each edit ensuring that results 
are genotype specific and not likely a result of unknown modifications during 
editing. PCR analysis and direct sequencing of the editing junctions confirmed all 
edited cells. Expression of the edited genes can be specifically monitored by 
qRT-PCR using a forward primer in the rat secretory sequence that is not present 
in the human genome. Details of sequences and methods used to construct this 
model can be found in Appendix A. 
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CHAPTER TWO 
NEURONAL DEVELOPMENT 
App and Aβ Insert Expression 
It is important to first establish the level of mRNA in edited samples for 
both the edit itself as well as the remaining unmodified App allele. While the 
exact function of APP is not known, a few reports have claimed a role in early 
development. I therefore measured both Aβ expression and App expression 
using qRT-PCR throughout development. There is a significant decrease in both 
Aβ1-40 and Aβ1-42 mRNA comparing stem cells to embryoid bodies (Figure 2).  
The pattern and extent of decrease appears similar for each edit. Following 
dissociation of EBs and differentiation into neurons there is a large increase in A 
expression and the pattern is similar for each edit, however, A1-40 appears to 
express more peptide mRNA (Figure 2). 
 
 15 
 
 
 
 
App expression also showed a similar pattern comparing Aβ1-40 and Aβ1-42 
NCs. As expected, expression of App in edited lines was approximately half the 
expression relative to unedited H9 cells (Figure 3). Somewhat unexpectedly, 
expression of the Aβ edited mRNA was ~37-fold less than App in edited 
genotypes relative to the unedited H9 cell line (Figure 3). This may potentially be 
 
Figure 2. Expression of Aβ1-40/42 Inserts at Different 
Developmental Stages. 
Expression of Aβ inserts was measured by qRT-PCR 
using primers in the secretory signal sequence which 
cannot be found in the human genome. In both cell 
lines, expression decreases from stem cells to neurons 
by ~24-fold. In Aβ1-40, expression from EB to neurons 
increased by ~308-fold. Expression in Aβ1-42 from EB to 
neurons increased by ~107-fold. Overall, both 
genotypes increase expression of the Aβ insert from SC 
to neuron by ~14-fold. 
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explained by functional disruption of an App enhancer sequence reported within 
the first intron of the gene as a result of cassette insertion in this region (Shakes 
et al., 2012). This reduced expression may in fact be beneficial since Aβ1-42 
peptide has acute proteotoxic properties and lower expression may allow 
development of more chronic toxicity as the peptide slowly accumulates as the 
neurons age, a situation similar to AD. In any case, the A mRNA levels are 
indistinguishable from background in unedited cells.  
 
 
 
Figure 3. Expression of App and Aβ in Neurons of 
All Three Genotypes. 
App expression in my Aβ1-42 and Aβ1-40 neurons is 
near half the expression of H9 neurons and not 
significantly different from each other. Expression of 
the Aβ1-40 and Aβ1-42 inserts are both 37-fold less 
than their respective App expressions.  
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Alzheimer’s is Not a Developmental Disease 
AD is not considered a developmental condition but rather a phenotype of 
old age. Before evaluation of direct A-dependent phenotypes in my cell lines it 
is crucial to first determine if they can differentiate normally. After EB 
dissociation, neurons begin to migrate into organized neuronal clusters (NC). 
These clusters grow larger as a function of culture time and eventually develop 
extensive neuronal processes and form synaptic connections within a particular 
cluster and apparently with adjacent NCs. Upon visual inspection using Hoffman 
differential interference microscopy, the neurons and NCs of unedited or either 
edited genotype appear similar in morphology and increase in size as they age 
(Figure 4). I compared the average area of NCs among all three genotypes at 6-
15 days, 16-25 days, and 26-35 days. Data were collected across independent 
differentiations to control for normal variability in culture morphologies. The 
average area of NCs appeared to increase. Statistical analysis of pooled data 
from multiple differentiations (ANOVA corrected for multiple comparisons using 
Dunnett’s method), however, failed to reach significance. There can be several 
potential technical reasons for this statistical anomaly. For example, it may have 
been better to measure volumes of NCs rather than area. The most likely reason, 
however, is that within a particular neuronal differentiation the increase in NC 
size is obvious but when pooling data form different individual neuronal 
differentiations the variations are greater than the increase in NC area. Ideally, 
this possibility could be tested by increasing the number of individual neuronal 
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differentiations however this was not possible due to time and expense 
considerations. The source of variation in stem cell differentiation is a well-known 
problem in stem cell biology of unknown cause. 
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Figure 4. Neuronal Clusters Appear Similar and Grow Larger As They Age. 
The appearance of the NCs of all three genotypes is similar up to 34 days and 
grow slightly larger as they age (top). The sizes of neuronal clusters at 
different age ranges were measured by manually tracing around the 
boundaries and measuring the area of several clusters within each culture. 
When the average areas are compared at each age range using ANOVA (with 
Dunnett’s multiple comparisons) there was no statistically significant 
difference. 
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To determine if the edits made to my cells affected the number of neurons 
that ultimately develop, I immunocytochemically stained and imaged 10 day old 
neurons AED (after embryoid body dissociation) for two neuron specific markers 
that are localized within two different cellular compartments. The first, NeuN, is a 
nuclear neuronal marker and the second, doublecortin (DCX), is a cytoplasmic 
neuronal marker. The neurons of all three genotypes at 10 days AED appear so 
similar in number and morphology that it is difficult to distinguish them (Figure 5). 
When the percentage of positive staining cells is compared among H9, Aβ1-40, 
and Aβ1-42 following image analysis, I find that there is no statistical difference for 
NeuN positive or DCX positive cells (Figure 5). 
Taken together, the results in this section suggest that all 3 genotypes 
analyzed can develop and differentiate normally (i.e. similar to the H9 parental 
genotype) and thus phenotypic analyses at later stages may be confidently 
predicted to be a result of edited peptide expression rather than effects on earlier 
developmental processes.   
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Figure 5. Edits Do Not Affect the Number of Neurons That Develop After 
Differentiation. 
Neurons were immunocytochemically stained for two neuronal markers, 
doublecortin (DCX) and NeuN 10 days AED. The number of cells positive for 
each type of neuronal marker were counted in several fields and the 
percentages of positive cells were compared. There was no difference by 
visual comparison in morphology and number (top) as well as by statistical 
analysis (bottom, ANOVA with Dunnett’s multiple comparisons test, N=15-38). 
Scale bar 30µm. 
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CHAPTER THREE 
ALZHEIMER’S-LIKE PHENOTYPES 
Aβ Aggregation 
An early hallmark of AD is aggregation and accumulation of the Aβ1-42 
peptide and thus measuring the aggregation of Aβ is a logical first step in 
examining differentiated neurons in my cultures. Aβ aggregation was measured 
immunocytochemically by staining 32-34 day old (AED) cultures with an antibody 
specific for the aggregated form of Aβ (7A1a) (Figure 6). Upon visual inspection, 
aggregated Aβ appears to be more abundant in Aβ1-42 NCs relative to A1-40. 
Quantification of the area of 7A1a staining, normalized to the area of neuronal 
marker Tuj1 to control for neuronal number indicates that Aβ1-42 NCs contain 
about 4.8 times more aggregated Aβ peptide when compared to unedited H9 
NCs and about 1.8 times more than Aβ1-40 NCs (Figure 6). Statistical analysis of 
the average of 7A1a area in NCs of each genotype reveals that the increased 
aggregation of Aβ is statistically significant (H9 vs Aβ1-42 P=0.0001 and Aβ1-40 vs 
Aβ1-42 P=0.0422). In addition to having increased Aβ aggregation, the aggregated 
Aβ also appears to localize near fragmented nuclei with especially bright 
fluorescence (Figure 7). 
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Figure 6. Aβ Aggregation in Neuronal Clusters 32 Days AED.  
NCs were immunocytochemically stained with an antibody specific for 
aggregated Aβ (7A1a). Upon visual comparison, Aβ1-42 NCs clearly contain 
significantly more aggregated Aβ1-42 than either H9 or Aβ1-40 (top). When 
these images are quantified and normalized to the amount of Tuj1 present (a 
neuronal marker), Aβ1-42 NCs contain 54%, Aβ1-40 30%, and finally H9 NCs 
average 11%. Statistical analysis of average percentages of 7A1a shows a 
significant difference between H9 and Aβ1-42 (P=0.0001) and H9 vs Aβ1-40 
(P=0.0422). Scale bar 10µm. 
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Synapse Decrease 
A decrease in synapses is an early stage cellular phenotype which has 
been well documented in AD and thought to be associated with mild cognitive 
deficits that appear in individuals long before more severe symptoms. I used 
immunocytochemistry to measure synapsin1 puncta as an index of synapses. 
Synapsin1 stains a protein present in synaptic vesicles. Individual vesicles are 
 
Figure 7. Aβ Aggregation is Localized Near Fractured Nuclei.  
7A1a staining at 34 days AED shows that aggregated Aβ is heavily localized 
around fractured nuclei (arrows, right image) and the nuclei of neurons with 
very little staining (arrow heads, right image) do not have this fractured 
appearance. The live/dead assays at 34 days AED show that these neurons 
with fragmented nuclei are likely to be dead and/or dying (left image, arrows). 
Scale bars 10µm. 
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below the resolution limit of light microscopy, but cluster in groups at neuronal 
synapses. Image analysis revealed a statistically significant 2.8-fold decrease in 
the number synapses present in Aβ1-42 neurons compared to H9 neurons (Figure 
8). 
 
 
 
 
 
Figure 8. Aβ1-42 Neurons Have Significantly Decreased Synapsin1 Puncta. 
Left, MIP of 0.5µm sections taken of H9 and Aβ1-42 NCs. H9 NCs averaged 
27.3 synapsin1 maxima/nucleus and Aβ1-42 NCs 9.9 maxima/nucleus 
(P=0.0203). Scale bar 20µm. 
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Neurodegeneration 
The later stages of AD are marked with increasing neuronal death in 
affected brain regions. A live/dead assay was used to estimate this phenotype in 
cultured cells at 10, 34, or 70 days AED (Figure 9). The method uses two 
fluorescent dyes to distinguish between live and dead cells: ethidium homodimer 
and calcein AM and is performed by incubating live neuronal cultures with a 
mixture of the indicators. Calcein AM is readily taken up by live cells but only 
fluoresces green when cleaved by cellular esterases which are not present in 
dead cells. Ethidium homodimer is live cell membrane impermeable but will 
fluoresce red when bound to DNA in dead cells with compromised 
plasma/nuclear membranes. At 34 days AED, there is no significant difference in 
cell death among the three genotypes. When the live/dead assay is repeated at 
70 days AED, there is a large increase in cell death for both Aβ1-40 and Aβ1-42 
genotypes relative to H9 parental cells (Figure 9). There is 2.3 times more cell 
death in Aβ1-42 NCs over H9 and about 2 times more death in Aβ1-40 NCs. To my 
knowledge this is the first mammalian experimental model that clearly exhibits a 
chronic progressive Adependent neurodegeneration phenotype and could thus 
be used to understand the mechanism of this process in human neurons. 
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Figure 9. Neuron Survival at 34 and 70 Days AED.  
A live/dead assay using calcein AM and ethidium homodimer was done on 
neurons at 34 days and 70 days AED. At 70 days AED Aβ1-42 NCs begin to 
take on a granulated appearance and the number of axonal projections is 
reduced (left, brightfield images). Neuron death was quantified by calculating 
the percentage of red (dead) area of each NC. There is no difference in cell 
death between genotypes at 34 days AED. At 70 days AED, H9 NCs average 
16%, Aβ1-40 33%, and Aβ1-42 38% red area. ANOVA with Dunnett’s multiple 
comparisons test reveals that the increase in cell death is significant (H9 vs 
Aβ1-40 P=0.0019 and H9 vs Aβ1-42 P=0.0001, N=7-92). Scale bar 50µm. 
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Changes in Gene Expression and Pathway Analysis 
Since my cells are isogenic, except for the edited alleles, they may be a 
good system to analyze the changes in gene expression that are dependent on 
direct expression of A1-42 or A1-42. mRNA was isolated from 34 day old neurons 
from multiple independently isolated clones of each genotype and characterized 
using RNA sequencing analysis. This provides data for the whole transcriptome 
rather than focusing on a preconceived hypothesized gene as is common in PCR 
based analyses. The differential gene expression (i.e. comparisons among 
samples with different genotypes) can provide unbiased clues to genes and 
pathways that are perturbed because of peptide expression and identify specific 
genes that could be targeted for therapeutic development and mechanistic 
analysis.  
Clustering of expression changes in multiple samples of different 
genotypes shows that Aβ1-42 clones group together and therefore have a similar 
expression pattern (Figure 10). Clustering of Aβ1-40 and H9 genotypes are 
interspersed suggesting that they have more similar expression patterns to each 
other than to the A1-42 samples (Figure 10).   
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Specific differentially expressed genes can be identified by plotting their 
expression p-values against their fold change. This results in a volcano plot 
 
Figure 10. Heatmap of Changes in Gene Expression. 
Gene expression of 34 day AED neurons was centered 
on the median per batch prior to clustering. Results 
indicate that quantitative gene expression determined by 
RNA-seq analysis groups the A1-42 samples together 
(i.e. they are similar to each other, relative to the A1-40 
or H9 genotypes). Note also that independently isolated 
clones cluster together. The data for H9 and A1-40 
indicates that individual samples are interspersed with 
each other with respect to gene expression. This is 
consistent with A1-42 having different phenotypes 
relative to either A1-40 or H9. 
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(when using the negative log of the p-values) allowing genes of high probability 
and high magnitude of change (either up or down regulated) to be easily 
visualized (Figure 11). When the top genes with changes in expression of both 
Aβ1-40 vs H9 and Aβ1-42 vs H9 are plotted together, there are some changes in 
expression that appear in both genotypes (Figure 12). This suggests that some 
differentially expressed genes in my edited cells (compared to unedited cells) 
may be due to the editing of one App allele rather than the expression of A 
peptide. Changes seen in Aβ1-42 but not in Aβ1-40 are most likely to be Aβ1-42 
specific. 
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Figure 11. Volcano Plots of Differentially Expressed Genes at 34 Days 
AED. 
Fold changes in gene expression were plotted as a function of their -
log(p-value) (i.e. the absolute value of their significance). Only 
expression changes 2 > 𝐹𝐶 < −2 and p<0.00001 are labeled in red (up 
regulated) or blue (down regulated. 
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Figure 12. Some Changes in Expression Are Likely Due to App Editing. 
The highest upregulated (top) and downregulated (bottom) genes of Aβ1-40 vs 
H9 and Aβ1-42 vs H9 at 34 days AED. Some changes in expression occur in 
both the Aβ1-40 and Aβ1-42 genotypes and may thus be due to editing of one 
App allele (highlighted in grey). Changes in expression that do not appear in 
Aβ1-40 are most likely to be Aβ1-42 dependent (highlighted in red).  
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Figure 13. IPA Analysis of RNA Sequencing Data. 
Ingenuity Pathway Analysis software was used to predict disease and 
function changes associated with differential gene expression of A1-42 
compared to H9. The two categories with the highest z-score were 
memory (z=-1.980) and neuronal cell death (z=1.658) and are depicted. 
Genes that are upregulated appear in shades of red and 
downregulated genes appear in green with the darker shades indicating 
a higher fold change in expression. The memory pathway appears in 
blue, indicating that the expression profile of Aβ1-42 neurons is likely to 
be inhibiting memory function. Neuronal cell death appears in orange, 
indicating that neuronal cell death pathways are likely to be activated. 
Remarkably, both of these phenotypes are key features of AD. 
Fold change 
Up-regulated 
Down-regulated 
Activated pathway 
Inhibited pathway 
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I also performed pathway analysis using Ingenuity software, a server 
based biological ontology. Remarkably the A1-42 vs H9 differential gene 
expression comparison revealed the two highest scoring (z-score, statistically 
normalized fold changes) for two functional/disease pathways: memory and 
neuronal cell death. These are the likely first and later stage phenotypes of AD. 
Figure 13 shows the pathways in a network diagram where individual genes are 
color coded relative to their differential expression and the arrows indicate 
predicted increases or decreases in the function/disease. In addition to these two 
pathways, there is also differential expression in several other genes associated 
with other pathways relevant to AD (Figure 14). 
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Figure 14. Differentially Expressed Genes Relevant to AD. 
RNA sequencing data of Aβ1-42 vs H9 differential expression of genes at 34 
days AED related to AD. The shapes of differentially expressed genes 
correspond to their known functions and the darker shades correspond to 
higher fold changes. Under each gene is the fold-change found in RNA 
sequencing data. Pathways listed at the bottom are all AD related and are 
associated with changes in the genes listed. The Aβ1-42 genotype shows 
expression changes of several genes in pathways related to AD. 
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CHAPTER FOUR 
SUMMARY AND DISCUSSION 
The genomic editing of my hESCs did not affect their ability to successfully 
differentiate into neurons. I measured the number of neurons present shortly 
after differentiation and found no difference between edited and unedited cell 
lines. After finding no differences in the number of neurons that develop, I 
followed and measured them as they aged. Up to 34 days, NCs appear similar in 
morphology and size. This was supported by the fact that when their area is 
measured, they are similar in size and increase similarly in size as they age.  
Aβ1-42 neurons have fewer synapsin1 puncta 32 days AED. Decreases in 
synapsin1 vesicles is an early and well-known cellular phenotype of AD. A 
decrease in the presence of synapsin1 has been previously shown to also 
coincide with dysfunction in the synaptic vesicle recycling pathway (Bogen et al., 
2006).  
The neurons in the Aβ1-42 line accumulate significantly more aggregated 
Aβ than either H9 or Aβ1-40 34 days AED. Aβ1-42 and Aβ1-40 neurons also 
experience nearly triple the amount of cell death as H9 70 days AED. This is 
consistent with the fact that AD is a chronic and progressive disease. The Aβ1-42 
neurons accumulate aggregated Aβ long before neuronal death begins in the 
same way that amyloid plaques appear decades before symptoms in AD 
patients. This is also supportive of the hypothesis that Aβ is causative in AD.  
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There is much debate as to whether intracellular or extracellular 
aggregation of Aβ is toxic to neurons. Immunocytochemical staining of my Aβ1-42 
neurons supports the intracellular hypothesis. Because of the nature of cell 
culture, medium is replaced often and culture in 2D likely prevents Aβ from 
accumulating outside of neurons. In addition to this, immunocytochemical 
staining with 7A1a antibodies shows that aggregated Aβ accumulation is mainly 
located near fractured nuclei. From my live/dead assays, I also know that these 
cells are dead and/or dying.  
RNA sequencing data of my neurons shows that independently isolated 
clones of each genotype cluster together and provides evidence that the 
phenotypes I see are not clone specific. There is also differential expression in 
several genes in pathways that are associated with AD, the most prominent of 
these being memory and neuronal cell death. When the most highly differentially 
expressed genes of Aβ1-40 vs H9 and Aβ1-42 vs H9 are compared, there is some 
overlap. These overlaps suggest that there may be some changes related to the 
editing of App.  
This cellular model has advantages over other models in that it has direct 
expression so the time and uncertainty of factors required to generate Aβ1-42 from 
APP are bypassed. Direct expression also eliminates the decades that is usually 
required for APP to be produced and accumulate within the brain, making this 
model suitable for a laboratory timescale. Since these cells are also isogenic the 
results obtained from this model are not confounded by the genetic variation that 
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often plagues iPSC and mouse models. This is supported by the fact that 
multiple independently isolated clones of each genotype show very limited 
differences. These cells are also heterozygous for ε4, an at-risk allele for AD. 
One disadvantage of this model is that it requires a reliable neuronal 
differentiation protocol. There is variation in the differentiation of these cells and I 
have found that during differentiation there is sometimes a non-genotype specific 
failure of cells to survive the process. Other members of the lab also experience 
this non-genotype specific survival failure. Another potential drawback of this 
model is that there are solely neurons present in these cultures. Thus, it cannot 
address interactions with or issues related to the blood brain barrier as well as 
contributions by astrocytes or microglia.  
While current and past models have provided researchers with answers 
about where Aβ comes from, how Aβ is processed from APP, and how Aβ 
aggregates, we still do not understand the mechanism behind how the neurons 
of AD affected patients are dying. Part of the reason for this is the lack of a model 
for AD that presents with clear AD phenotypes, namely neurodegeneration, as 
well as possible species differences between animal models and humans. This 
newly created model focuses on Aβ1-42 dependent phenotypes and addresses 
both concerns by utilization of hESCs with direct expression of Aβ1-42. By directly 
expressing Aβ1-42 in human cells, this model also eliminates the time and 
uncertainty of factors required to generate Aβ1-42 from APP as well as the 
decades that it usually takes to accumulate Aβ. I have demonstrated that these 
 39 
 
edited stem cells can successfully differentiate into neurons without any 
significant abnormalities and later develop many of the characteristic 
neuropathologies of AD in culture. This is the first known model of Aβ1-42 
dependent ND in human neurons and could thus be used to identify therapeutic 
agents that slow or prevent this process and in addition may help elucidate the 
possible mechanisms behind neuronal death in AD. 
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CHAPTER FIVE 
MATERIALS AND METHODS 
Cell Culture and Maintenance 
Cell Lines 
WA09 H9 human embryonic stem cells were obtained from the WiCell Research 
Institute (Madison, WI, USA). TALEN editing was used to insert Aβ1-42 or Aβ1-40 
sequence in the first exon of one APP allele. Cassette sequences can be found 
in Appendix A. 
Stem Cell Maintenance 
Stem cells were maintained on DR4 IRR mouse embryonic fibroblasts 
(MTI Global Stem; Gaithersburg, MD, USA) in HuES medium. HuES medium is 
Dulbecco’s Modified Eagles Medium: nutrient mixture F-12 (DMEM/F12: Gibco), 
20% KnockOutTM Serum Replacement (Invitrogen), 50 U Penicillin and 50 mg/mL 
Streptomycin (Penicillin-Streptomycin, Gibco), 1% MEM Non-essential Amino 
Acids (Gibco), 1mM GlutaMax (Gibco), 0.1 mM β-Mercaptoethanol (Sigma), and 
20ng/mL basic fibroblast growth factor (bFGF; Stemgent). 
Neuronal Differentiation 
Cells were differentiated according to a modified protocol based on a previously 
established protocol (Amoroso et al., 2013). 
Embryoid body generation: On day zero, confluent wells of stem cells were 
passaged by incubation with Dispase (1mg/mL, Stem Cell Technologies) for 10-
15 minutes. Cells were then washed twice with DPBS and triturated in 1mL of 
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PBS. Cells were then resuspended to 4x105 cells/mL in HuES supplemented with 
10µM Y-27632 (StemGent), 10µM SB-431542 (StemGent), 0.2µM LDN-193189 
(StemGent) and plated in 10cm petri dishes coated with 6mL of 1.5% Agar (or 
ultra-low attachment dishes). Day two: Embryoid Bodies were collected into 
50mL conical tubes, allowed to settle for 45 minutes, and as much media was 
removed from the cells before plating again in the same media as day zero. Day 
three: Collect embryoid bodies as on day two and change to Neural Induction 
Medium (NIM) supplemented with 20ng/mL bFGF, 10µM Y-27632, 10µM SB-
431542, and 0.2µM LDN-193189. NIM is DMEM/F12, 50U Penicillin, 50mg/mL 
streptomycin, 1% Non-essential Amino Acids, 1mM Glutamax, 1x N-2 
Supplement (Gibco), and 2µg/mL Heparin (Sigma-Aldrich). Day five: Collect cells 
as above and switch to NIM with 20ng/mL bFGF, 10µM SB-431542, 0.2µM LDN-
193189, 10ng/mL brain-derived neurotrophic factor (BDNF, PreproTech), 
0.4µg/mL Ascorbic Acid (AA, Sigma), 1µM Retinoic Acid (RA, Sigma). Day 7-15: 
Collect cells as above and use NIM supplemented with 10ng/mL BDNF, 
0.4µg/mL AA, 1µM RA, 2µM Smoothened agonist (SAG, Calibochem). Change 
media every 2-3 days. Day 17+: Collect cells as above and switch to Neural 
Differentiation Medium (NDM) supplemented with 10ng/mL BDNF, 0.4µg/mL AA, 
1µg/mL RA, 2µg/mL SAG, 1x B-27 supplement (Gibco), 10ng/mL glial cell line-
derived neurotrophic factor (GDNF, PreproTech), 10ng/mL ciliary neurotrophic 
factor (CNTF, PreproTech), 10ng/mL insulin-like growth factor 1 (IGF-1, 
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PreproTech). Change media every 2-3 days. Dissociate EB bodies anytime 
between days 24 through 28.  
Embryoid body dissociation: EBs are collected and rinsed in calcium and 
magnesium-free PBS (Corning Cell Grow). Then they were incubated with trypsin 
for 1-4 minutes. Then one equal volume fetal bovine serum (FBS, Hyclone) and 
two volumes of complete trituration wash medium (CTWM) are added. CTWM 
consists of calcium and magnesium free PBS, 25mM glucose (Mallinchrodt), 
0.1% dialyzed bovine serum albumin (BSA, Roche), 1x N-2 supplement, 1x B-27 
supplement, 2mM MgCl2, 1mM ethylenediaminetetraacetic acid (EDTA, J.T. 
Baker), and 2.5% FBS. Centrifuge cells at 1400rpm for three minutes. Remove 
supernatant and re-suspend in 1mL of CTWM. Then triturate clumps with a 
p1000 pipette for seven passes. Add 10-12mL of CTWM and filter through a 
40µm filter (Corning). Record volume and count cells. Centrifuge at 1400rpm for 
4 minutes and resuspend cells in NDM supplemented with 1x B-27 supplement, 
10ng/mL BDNF, 10ng/mL GDNF, 10ng/mL IGF-1, 10ng/mL CNTF, 0.4µg/mL AA, 
25µM glutamate, 25µM β-mercaptoethanol, and 1mM RA. Seed cells at 1.5 -
1.8x106 cells per well of a 6-well plate coated with laminin (company) and poly-
ornithine (company). Laminin in DMEM/F12 (15µg/mL) is coated 48 hours prior to 
cell plating for 24 hours and poly-ornithine in DMEM/F12 (100µg/mL) is coated 
after for 24 hours prior to cell plating.  
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Neuron Maintenance 
Neurons were maintained in NDM supplemented with 1x B-27 supplement, 
10ng/mL BDNF, 10ng/mL GDNF, 10ng/mL IGF-1, 10ng/mL CNTF, 0.4µg/mL AA, 
25µM glutamate, 25µM β-mercaptoethanol, and 1mM RA. Cultures were treated 
with 0.5µM ethynyl deoxyuridine (EdU) for 24 hours once a week, starting on the 
day of dissociation until day 50 post EB dissociation to maintain post-mitotic 
neurons only. 
Quantitative Real-Time PCR 
Total RNA extraction was done using RNeasy Micro Kit from (Qiagen) 
using the manufacturer’s protocol. One well of a 6-well plate of healthy neurons 
usually yields approximately 1x106 cells and 1-3µg of total RNA. RNA 
concentration and purity were determined using a NanoDrop ND-1000 
Nanospectrophotometer (ThermoFisher Scientific). cDNA was prepared using 
qScript cDNA SuperMix (Quanta) following the manufacturers protocol. All qRT-
PCR reactions were carried out in a 20µl reaction mixture containing 12.5µl iQTM 
SYBR® Green Supermix (Bio-Rad), 2µM of each forward and reverse primer, 
0.25µg cDNA, and DEPC-Treated Water (Ambion) to adjust the final volume to 
20µL. Amplification was carried out using a BioRad CFX96 TouchTM Real-Time 
PCR Detection System in clear 96 well sealed plates. 
Cycling Conditions were as follows:  
Initial denaturation/enzyme activation 95°C for 3 minutes 
Denature: 95°C for 30 seconds 
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Annealing and Extension: 55°C for 20 seconds, 40 cycles 
Melt Curve: 55°C to 95°C for 5 seconds in 0.5°C increments  
 
 
 
 
Immunocytochemistry 
Cells were grown on 15mm No.1 coverslips (FisherScientific) and 
incubated with freshly made 4% Paraformaldehyde for 20 minutes. Then, 4% 
Paraformaldehyde is removed and cells are washed with PBS for 5 minutes 3x. 
Coverslips were stored in 0.03%NaN3 PBS at 4°C until use.  
For Immunostaining, coverslips were incubated with blocking buffer (0.3% 
Triton X-100 and 5% Bovine Serum Albumin in PBS) for 45 minutes at room 
temperature. Blocking buffer is then removed, coverslips are briefly rinsed with 
PBS, and primary antibodies diluted in antibody buffer (0.3% Triton x-100 and 
1% Bovine Serum Albumin in PBS) are added. Cells are incubated in primary 
antibodies overnight at 4°C. Primary antibodies are then removed and coverslips 
Table 1. Quantitative Real-Time PCR Primers 
 
Primer Forward (5’→3’) Reverse (5’→3’) 
APP5* GAGGAGGATGACTCGGATGTCTGG GGTGGTTCTCTCTGTGGCTTCTTCGT 
GAPDH ATGGGGAAGGTGAAGGTCGGAGTC GGGATTTCCATTGATGACAAGCTTCCCG 
Aβ† ATGGCGCAGTTCCTGAGA ATGATTGCACCTTTGTTTGAACC 
 
*App5 primer spans the junction between exons 5 and 6  
† primer is the beginning of the secretory signal sequence (not found in the human genome) 
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are washed with PBS for 5 minutes 3x. Secondary antibodies are diluted with 
antibody buffer and are then added to the coverslips and incubated for two hours 
at room temperature protected from light. The secondary antibody solution is 
then removed and coverslips are washed again with PBS for 5 minutes 3x. 
Coverslips are then incubated with DAPI (1µg/µl) for 5 minutes at room 
temperature protected from light and washed with PBS for 5 minutes 2x. 
Coverslips were then mounted onto glass slides using Dako Fluorescent 
Mounting Medium. Fluorescent images were taken using the Zeiss Observer II 
microscope using either of the following objectives: 63X/1.4NA Plan-Apochromat 
DIC OIL or 20X/0.80NA Plan-Apochromat DIC and a Zeiss AxioCam 506. ZEN 
Blue software was used to capture images. 
 
 
Table 2. Antibodies Used for Immunocytochemistry 
 
Antibody Dilution Supplier Catalog No. 
NeuN 2µg/mL Abcam Ab104224 
Lamp1 0.25µg/mL Abcam Ab24170 
DCX 1µg/mL Abcam Ab77450 
Oligomeric Aβ (7A1a) 1.4µg/mL New England Rare Reagents N/A 
Synapsin I 0.2µg/mL Abcam Ab8 
Goat anti-Chicken IgY H&L  
(Alexa Flour 488) 
3.9-3.98µg/mL Abcam Ab150169 
Goat anti-Rabbit IgG H&L 
(Alexa Flour 488) 
2µg/mL Abcam Ab150077 
Goat anti-Mouse IgG H&L 
(Alexa Flour 594) 
2µg/mL Invitrogen A11005 
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Image Analysis 
All image handling and processing was done with Fiji image analysis 
software (Schindelin et al., 2012). NeuN and DCX positive cells were counted 
and normalized to the total number of DAPI stained nuclei present in the same 
field. NeuN and DAPI were both counted using the Otsu method in ImageJ and 
DCX positive cells were counted manually. Oligomeric Aβ (7A1a) quantification 
was done by creating a tightly bound box around each individual neuronal cluster 
and cropping the image to this area. Background was subtracted using a 150-
pixel rolling ball radius. A maximum intensity projection was then created from an 
image stack (0.5m Z intervals, 16-60 images), then using the Z-projection 
maximum intensity algorithm. The individual color channels were separated and 
the Aβ channel was thresholded using the IsoData method to measure the area 
of positive staining within the neural cluster and expressed as a percentage of 
the total cluster area. Neuronal cluster area was measured from Hoffman 
interference contrast images by using the freehand tool to manually trace the 
edges of clusters and using the measure area function.  
Live/dead analysis was done by staining neuronal clusters growing on 
coverslips or in 12 well plates using ethidium homodimer (red fluorescence, dead 
cells) and calcein AM esterase substrate (green fluorescence when hydrolyzed). 
Three to five individual focal planes were obtained as well as a reference 
Hoffman interference contrast image. The number of pixels in an area was 
measured by separating individual color channels of the stack, subtracting 
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background using a 50-pixel rolling ball radius and creating a maximum intensity 
projection using auto brightness and contrast to threshold each channel. Data is 
presented as percent red area relative to the total area of red plus green 
channels.  
Synapsin1 puncta quantification was done by subtracting the background 
using a 150-pixel rolling ball radius and creating a maximum intensity projection 
of a stack of images (0.5µm sections, 11-31 images). The nuclei were counted 
the same way as in the DCX and NeuN analysis and the synpasin1 puncta were 
counted using the ImageJ find maxima function. The number of synapsin1 
puncta were then normalized to the number of DAPI nuclei present in each NC.  
Brightfield Imaging 
Brightfield Hoffman Modulated Contrast (HMC) images were taken using a 
Nikon Diaphot microscope using either of the following objectives: HMC EF 10X 
0.25NA 160/- or HMC 20X LWD 0.4NA 160/0-2. A SPOT RT230 camera and 
SPOT Advanced software was used to capture images.  
Statistical Analysis 
All statistical analyses were done using at least three biological replicates 
and more than one clone per edited genotype. Each differentiation from stem cell 
expansion to neuron is considered one biological replicate. GraphPad Prism 7 
software was used for all statistical calculations.  
 
 48 
 
 
 
 
 
 
 
 
APPENDIX A 
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Creation of the cell lines used in this research were carried out previously 
by members of the Salvaterra lab using TALEN. The sequences of the inserts 
include an ATG start codon followed by the rat preproenkephin sequence, the 
Aβ1-40 or Aβ1-42 sequence ending with a stop codon, followed by a pgk promoter 
with a puromycin selection gene and polyA tail all inserted within the first exon of 
App (Figure 15).  
 
APP exon 1, bases in red were cut out by TALENs: 
GGATCAGCTG ACTCGCCTGG CTCTGAGCCC CGCCGCCGCG CTCGGGCTCC GTCAGTTTCC 
TCGGCAGCGG TAGGCGAGAG CACGCGGAGG AGCGTGCGCG GGGGCCCCGG GAGACGGCGG 
CGGTGGCGGC GCGGGCAGAG CAAGGACGCG GCGGATCCCA CTCGCACAGC AGCGCACTCG 
GTGCCCCGCG CAGGGTCGCG ATGCTGCCCG GTTTGGCACT GCTCCTGCTG GCCGCCTGGA 
CGGCTCGGGC GCTGGAG 
 
 
Diagram of edited App locus 
The inserted cassette is within the first exon of App. The Cassette contains a start 
codon followed by a secretory sequence, the Aβ1-42/40 sequence, puromycin selection, 
and finally a polyA tail.  
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Aβ1-42 insert: 
ATGGCGCAGT TCCTGAGACT TTGCATCTGG CTCGTAGCGC TTGGGTCCTG CCTCCTGGCT 
ACAGTGCAGG CAGATGCAGA ATTCCGACAT GACTCAGGAT ATGAAGTTCA TCATCAAAAA 
TTGGTGTTCT TTGCAGAAGA TGTGGGTTCA AACAAAGGTG CAATCATTGG ACTCATGGTG 
GGCGGTGTTG TCATAGCGTAG 
 
Aβ1-40 insert: 
ATGGCGCAGT TCCTGAGACT TTGCATCTGG CTCGTAGCGC TTGGGTCCTG CCTCCTGGCT 
ACAGTGCAGG CAGATGCAGA ATTCCGACAT GACTCAGGAT ATGAAGTTCA TCATCAAAAA 
TTGGTGTTCT TTGCAGAAGA TGTGGGTTCA AACAAAGGTG CAATCATTGG ACTCATGGTG 
GGCGGTGTTG TCTAG 
 
Pgk promoter with puro selection gene and poly A tail: 
ATTCTACCGG GTAGGGGAGG CGCTTTTCCC AAGGCAGTCT GGAGCATGCG CTTTAGCAGC 
CCCGCTGGGC ACTTGGCGCT ACACAAGTGG CCTCTGGCCT CGCACACATT CCACATCCAC 
CGGTAGGCGC CAACCGGCTC CGTTCTTTGG TGGCCCCTTC GCGCCACCTT CTACTCCTCC 
CCTAGTCAGG AAGTTCCCCC CCGCCCCGCA GCTCGCGTCG TGCAGGACGT GACAAATGGA 
AGTAGCACGT CTCACTAGTC TCGTGCAGAT GGACAGCACC GCTGAGCAAT GGAAGCGGGT 
AGGCCTTTGG GGCAGCGGCC AATAGCAGCT TTGCTCCTTC GCTTTCTGGG CTCAGAGGCT 
GGGAAGGGGT GGGTCCGGGG GCGGGCTCAG GGGCGGGCTC AGGGGCGGGG CGGGCGCCCG 
AAGGTCCTCC GGAGGCCCGG CATTCTGCAC GCTTCAAAAG CGCACGTCTG CCGCGCTGTT 
CTCCTCTTCC TCATCTCCGG GCCTTTCGAC CTGCAGCCCA AGCTTACCAT GACCGAGTAC 
AAGCCCACGG TGCGCCTCGC CACCCGCGAC GACGTCCCCA GGGCCGTACG CACCCTCGCC 
GCCGCGTTCG CCGACTACCC CGCCACGCGC CACACCGTCG ATCCGGACCG CCACATCGAG 
CGGGTCACCG AGCTGCAAGA ACTCTTCCTC ACGCGCGTCG GGCTCGACAT CGGCAAGGTG 
TGGGTCGCGG ACGACGGCGC CGCGGTGGCG GTCTGGACCA CGCCGGAGAG CGTCGAAGCG 
GGGGCGGTGT TCGCCGAGAT CGGCCCGCGC ATGGCCGAGT TGAGCGGTTC CCGGCTGGCC 
GCGCAGCAAC AGATGGAAGG CCTCCTGGCG CCGCACCGGC CCAAGGAGCC CGCGTGGTTC 
CTGGCCACCG TCGGCGTCTC GCCCGACCAC CAGGGCAAGG GTCTGGGCAG CGCCGTCGTG 
CTCCCCGGAG TGGAGGCGGC CGAGCGCGCC GGGGTGCCCG CCTTCCTGGA GACCTCCGCG 
CCCCGCAACC TCCCCTTCTA CGAGCGGCTC GGCTTCACCG TCACCGCCGA CGTCGAGGTG 
CCCGAAGGAC CGCGCACCTG GTGCATGACC CGCAAGCCCG GTGCCTGAAT CCGTCGAGGA 
ATTCACTCCT CAGGTGCAGG CTGCCTATCA GAAGGTGGTG GCTGGTGTGG CCAATGCCCT 
GGCTCACAAA TACCACTGAG ATCTTTTTCC CTCTGCCAAA AATTATGGGG ACATCATGAA 
GCCCCTTGAG CATCTGACTT CTGGCTAATA AAGGAAATTT ATTTTCATTG CAATAGTGTG 
TTGGAATTTT TTGTGTCTCT CACTCGGAAG GACATATGGG AGGGCAAATC ATTTAAAACA 
TCAGAATGAG TATTTGGTTT AGAGTTTGGC AACATATGCC CATATGCTGG CTGCCATG 
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RNA Sequencing data of Aβ1-42 vs H9 
Table includes differentially expressed genes with a fold change = |1.5| and a 
false discovery rate <0.05. 
 
ID Fold Change (FC) p-value False Discovery Rate (q) 
AGTR2 4.47 0.000000238 0.000167 
ANKRD20A12P 3.12 0.000000142 0.000118 
AQP3 2.22 0.000103 0.023 
ARC 2.85 0.0000172 0.00583 
AVPR1A 1.95 0.00000309 0.00161 
BARX1 1.79 0.00023 0.0415 
C7 2.11 0.000189 0.0363 
CALHM2 1.74 0.0000722 0.018 
CLDN6 2.57 0.000179 0.0352 
COL13A1 2.28 0.0000655 0.0169 
COL6A3 2.38 2.55E-08 0.0000359 
COLEC10 2.11 0.0000285 0.00883 
CPNE6 2.35 0.0000956 0.0218 
DACH1 2.69 0.0000704 0.0179 
DIO3 3.01 7.57E-09 0.0000126 
DLK1 3.92 0.000000105 0.0000927 
EDNRB 9.58 7.63E-28 6.97E-24 
FAM150A 2.97 0.000000209 0.000159 
FENDRR 2.79 0.000000107 0.0000927 
FOSB 2.69 0.00000439 0.00216 
GATA2 2.46 0.0000176 0.00583 
GEM 4 0.000000224 0.000164 
HBD 12.38 2.23E-13 6.79E-10 
HS3ST2 2.69 0.0000365 0.0106 
HSPA6 3.92 8.1E-13 1.85E-09 
ID1 2.99 0.0000923 0.0216 
IL11 2.53 0.00000297 0.0016 
IRX4 1.64 0.000132 0.0283 
NPAS4 2.62 0.000121 0.0264 
NPTX1 2.95 0.000000166 0.000132 
NR1H4 4.44 9.74E-19 5.93E-15 
NR4A1 2.79 0.0000173 0.00583 
PITX1 2.5 4.51E-08 0.0000549 
PLAT 2.91 0.0000164 0.00583 
PRELP 2.53 3.31E-08 0.0000432 
PRR32 2.08 0.00006 0.0159 
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RARRES2 3.66 0.000000278 0.000188 
SLITRK6 2.08 0.00000549 0.00257 
SP8 2.36 1.89E-14 6.92E-11 
TBX3 2.07 0.000187 0.0363 
TBX4 1.55 0.000203 0.0382 
UTF1 2.13 0.0000345 0.0102 
ZNF253 9.06 0.00000246 0.00136 
ZNF732 1.78 0.00000195 0.00111 
ZPLD1 1.97 0.0000787 0.0192 
AKAP14 -2.23 0.000286 0.0497 
ANXA13 -3.53 7.15E-08 0.0000768 
APOH -2.25 0.000105 0.0231 
C10orf105 -3.53 0.000136 0.0288 
C10orf11 -2.06 0.000169 0.0339 
C11orf88 -1.78 0.000285 0.0497 
C14orf105 -2.75 0.00000924 0.00401 
C4BPA -2 0.0000202 0.00658 
C5orf66 -2.41 0.0000941 0.0218 
CD36 -4.17 1.03E-09 0.00000194 
CFAP161 -2.71 0.0000425 0.0119 
CLIC5 -3.66 0.000000493 0.00031 
COL8A1 -1.99 0.0000119 0.00488 
CXorf57 -1.61 1.06E-09 0.00000194 
DAW1 -3.61 0.0000657 0.0169 
DGKK -2.28 0.000000382 0.000249 
EGFLAM -1.68 0.000156 0.0317 
FAM166B -2.57 0.000254 0.0455 
FAM216B -3.27 1.79E-08 0.0000273 
FMO1 -1.73 5.92E-08 0.0000676 
FNDC1 -1.95 0.000156 0.0317 
FOXG1 -2.2 0.00000694 0.00317 
GALNT3 -2.89 0.000154 0.0317 
GAS2L2 -1.95 0.000209 0.0386 
GDA -3.1 0.0000447 0.0123 
HP -3.16 0.0000172 0.00583 
INSRR -3.07 0.000014 0.00526 
JPH2 -2.04 0.00000921 0.00401 
KCNMB1 -1.79 0.000000102 0.0000927 
LINC00880 -2.3 0.00000493 0.00237 
LINC00930 -1.93 0.0000451 0.0123 
LINC01132 -2.17 0.000141 0.0295 
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LINC01139 -4.53 0.00000112 0.00066 
LOC200726 -1.67 0.0000386 0.011 
LRRC71 -2.66 0.0000492 0.0132 
MAOA -1.92 0.0000141 0.00526 
MMRN1 -2.43 0.000207 0.0386 
NDST4 -2.27 0.000259 0.0459 
NME8 -2.19 0.000229 0.0415 
NPY6R -1.72 0.0000847 0.0204 
NTRK1 -3.03 0.0000125 0.00488 
OMD -1.58 0.0000309 0.00941 
PCDHB17P -2.33 0.000179 0.0352 
SERPIND1 -3.2 0.0000315 0.00941 
SHISA2 -2.14 0.00000323 0.00164 
SLC12A1 -3.05 0.000000104 0.0000927 
STXBP6 -3.53 0.000000536 0.000326 
TMC5 -2.45 0.0000729 0.018 
USH2A -1.83 0.0000103 0.00437 
ZNF135 -7.06 6.4E-13 1.67E-09 
ZNF506 -2.2 1.47E-17 6.72E-14 
ZNF542P -3.27 4.62E-30 8.43E-26 
ZNF582 -2.01 0.0000122 0.00488 
ZNF582-AS1 -1.95 0.0000224 0.00718 
ZNF585B -3.1 0.000201 0.0382 
 
RNA Sequencing data of Aβ1-40 vs H9 
Table includes differentially expressed genes with a fold change = |1.5| and a 
false discovery rate <0.05. 
 
ID Fold Change(FC) p-value False Discovery Rate (q) 
AGTR2 2.04 0.0000353 0.0143 
ANGPTL1 2.23 0.0000946 0.032 
ANKRD20A12P 3.68 4.11E-09 0.00000683 
AVPR1A 2 0.0000317 0.0135 
C7 2.39 0.0000402 0.016 
CALB1 2.17 0.000144 0.0425 
COL6A3 5.66 1.39E-08 0.0000169 
CSRP1 3.14 1.38E-09 0.00000315 
CXorf57 3.48 4.38E-11 0.000000133 
DIO3 3.76 0.00000177 0.00108 
DLK1 3.18 0.00009 0.031 
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DNAJA4 2.93 0.00000264 0.00155 
EDNRB 3.71 2.9E-21 1.77E-17 
FAM150A 2.38 0.000143 0.0425 
FENDRR 2.93 1.12E-08 0.0000158 
GATA2 4.11 0.00000133 0.000837 
GDF10 2.73 0.000000176 0.000146 
GEM 2.85 0.0000706 0.0253 
GFAP 2.17 0.000000551 0.000373 
H19 71.51 8.06E-58 1.47E-53 
HSPA6 2.25 0.00000581 0.00312 
IRS4 4.03 0.000000485 0.00034 
LGR5 1.62 0.0000537 0.02 
PRODH 2.41 0.000111 0.0363 
LRRC61 2.25 4.77E-08 0.0000484 
NPTX1 2.69 0.0000268 0.012 
NR1H4 5.46 7.9E-17 2.88E-13 
PAX2 2.48 1.74E-08 0.0000199 
PITX1 2.51 6.67E-08 0.0000641 
PLAT 2.22 0.0000516 0.0196 
PNPLA4 7.62 7.79E-24 7.11E-20 
POTEM 2.1 0.0000681 0.0249 
POU4F1 2 0.000111 0.0363 
PRELP 2.25 0.00000348 0.00198 
RARRES2 2.38 0.00000124 0.000807 
S100A6 4.53 3.34E-09 0.00000609 
SERPINE1 3.76 0.0000311 0.0135 
SIX6 6.77 0.000000339 0.000247 
SLC14A1 1.64 0.0000432 0.0168 
SLITRK6 2.19 0.0000214 0.0103 
SST 1.75 0.000135 0.0417 
SYT10 2.71 0.0000242 0.0113 
TBX3 3.25 0.0000726 0.0255 
TBX4 2.22 0.00000033 0.000247 
TCEAL5 4.03 0.000000281 0.000223 
TNFRSF11B 3.07 0.0000047 0.0026 
TRIM58 3.56 1.32E-08 0.0000169 
VAMP5 4.14 0.000141 0.0425 
ZFP3 4.56 8.63E-09 0.0000131 
ZIC4 1.96 0.000116 0.0368 
ZNF253 9.51 0.0000165 0.00835 
ZNF595 2.58 0.00000976 0.00509 
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ZNF680 3.78 7.43E-21 3.39E-17 
ZNF790-AS1 2.71 5.76E-11 0.00000015 
ZSCAN1 3.32 0.000000111 0.0000965 
BEX5 -10.7 8.26E-08 0.0000754 
C4BPA -2.5 0.0000348 0.0143 
LINC01139 -9.92 3.21E-09 0.00000609 
LINC01146 -3.66 0.000117 0.0368 
MLC1 1.44 0.0000253 0.0116 
NPY6R -2.22 0.0000204 0.01 
PENK -2.83 3.21E-08 0.0000345 
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